Lorlatinib for advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC): efficacy and safety data from IFCT1803 LORLATU Expanded Access Program (EAP) cohort

  • Etude concernée: IFCT-1803
  • Auteurs / Authors: N. Girard, S. Galland Girodet M. Duruisseaux, V. Avrillon, B. Roch, J. Otto, J. Cadranel, M. Coudurier, D. Moro-Sibilot, T. Egenod, R. Lamy, J. Bennouna, G. Zalcman, C. Ricordel, J. Tillon, L. Odier, B. Besse, P. Missy, V. Westeel, S. Baldacci
  • Journal / Conference: ESMO
  • Année / Year: 2020
  • PMID: Poster
  • Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41659-X/abstract